{
  "source": "PA-Notification-Hympavzi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 1473-1\nProgram Prior Authorization/Notification\nMedication Hympavzi™ (marstacimab-hncq)\nP&T Approval Date 3/2025\nEffective Date 7/1/2025\n1. Background:\nHympavzi (marstacimab-hncq) is a tissue factor pathway inhibitor (TFPI) antagonist indicated for\nroutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric\npatients 12 years of age and older with:\n• hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors\n• hemophilia B (congenital factor IX deficiency) without factor IX inhibitors\n2. Coverage Criteriaa:\nA. Hemophilia A Without Inhibitors\n1. Initial Authorization\na. Hympavzi will be approved based on all of the following criteria\n1) Diagnosis of hemophilia A\n-AND-\n2) Patient is 12 years of age or older\n-AND-\n3) Prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis)\n-AND-\n4) Patient does not have a history of inhibitors to factor VIII\nAuthorization of therapy will be issued for 12 months.\n2. Reauthorization\na. Documentation of positive clinical response to Hympavzi therapy\nAuthorization will be issued for 12 months.\nB. Hemophilia B Without Inhibitors\n1. Initial Authorization\n© 2025 UnitedHealthcare Services Inc.\n1\na. Hympavzi will be approved based on all of the following criteria\n1) Diagnosis of hemophilia B\n-AND-\n2) Patient is 12 years of age or older\n-AND-\n3) Prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis)\n-AND-\n4) Patient does not have a history of inhibitors to factor IX\nAuthorization of therapy will be issued for 12 months.\n2. Reauthorization\na. Documentation of positive clinical response to Hympavzi therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinic",
    " Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim\nlogic. Use of automated approval and re-approval processes varies by program and/or\ntherapeutic class.\n• Medical Necessity may be in place.\n4. References:\n1. Hympavzi™ [package insert]. New York, NY: Pfizer Inc., October 2024.\nProgram Prior Authorization/Notification - Hympavzi (marstacimab-hncq)\nChange Control\n3/2025 New program.\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}